Monday, 16 November 2026 X LinkedIn Bluesky RSS Send us news
LungDaily The Pulse of Respiratory Health
World COPD Day is on Wednesday 18 November · #WorldCOPDDay Our coverage →
New Paper Alert

Fewer children with EoE on dupilumab developed asthma than those on budesonide

A Healio Pulmonology post on X reports findings presented at ACAAI26 comparing incident asthma in children with eosinophilic oesophagitis treated with dupilumab or budesonide.

“Significantly fewer children with eosinophilic esophagitis (#EoE) receiving dupilumab developed incident #asthma than those receiving budesonide.”— Healio Pulmonology

Significantly fewer children with eosinophilic oesophagitis (EoE) who received dupilumab developed incident asthma than those who received budesonide, according to findings presented at ACAAI26.

The result was reported in a post on X by Healio Pulmonology on 14 November 2026. The post, which also tagged @ACAAI, @HealioAllergy and @HealioGastro, compared the two treatments in terms of the development of new asthma in children with EoE.

The post does not give further details of the study, including its design, the number of children involved, the size of the difference between the groups or the follow-up period. It also does not name a journal or the researchers behind the work.

Original source

#asthma#paediatrics#therapeutics

Related stories

More in New Paper Alert

See all

LungDaily reports on public posts, papers and news from the lung health community. This article is based on the source linked above and was produced with AI-assisted tools under our editorial standards; facts and quotes are checked against the original before publication. Featured here, or spotted an error? Request a correction or removal.